Antoni Ribas
MD, PhD

Dr. Ribas is Professor of Medicine, Professor of Surgery and Professor of Molecular and Medical Pharmacology at UCLA. He is also Director of the Tumor Immunology Program at Jonsson Comprehensive Cancer Center, Director of the Parker Institute for Cancer Immunotherapy Center, UCLA, and Chair of the SWOG Melanoma Committee. He is a member of the American Society of Clinical Investigation. Dr. Ribas is a recipient of the AACR Richard and Hinda Rosenthal Award and NCI Outstanding Investigator Award.

Ralph R. Weichselbaum
MD

Dr. Weichselbaum is Daniel K. Ludwig Distinguished Service Professor of Radiation and Cellular Oncology, and Chair, Department of Radiation and Cellular Oncology, University of Chicago. He has made discoveries in basic signal transduction after ionizing radiation exposure & in separate studies, discovered that mechanisms of radiation resistance/sensitivity are mediated by cytokine activation in tumors. He is currently investigating the relationship between radiotherapy & immunotherapy.

Michael Doherty

Michael Doherty joined in 2020 with extensive knowledge of regulatory affairs and product development, including a focus on precision medicine. He was Head of R&D and Head of Product Development at Foundation Medicine Inc. During more than 14 years at Hoffmann La Roche / Genentech, his roles included Head of Strategic Innovation, Pharma Development, and Global Head, Pharma Regulatory Affairs. He led Global Regulatory Affairs as Roche launched its leading oncology portfolio of monoclonal antibodies and targeted medicines. He was a member of Roche’s portfolio committee from 2002 to 2016. Mr. Doherty previously worked for AstraZeneca, Rhone-Poulenc Rorer and Sandoz.

Professor Georgina Long
AO BSc PhD MBBS FRACP

Professor Georgina Longis Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and the University of Sydney. Professor Long is a key opinion leader in the field of Melanoma and Medical Oncology. She leads an extensive clinical trials team and laboratory at MIA, with a focus on molecular biology of Melanoma, with a particular interest in clinical and tissue and biomarker correlated of systemic therapy sensitivity and resistance.

In recognition of her ground-breaking research, Professor Long has received numerous awards including, Cancer Institute New South Wales Premier’s Award for Outstanding Cancer Researcher 2018. She has a prodigious publication record, sits on numerous Advisory Boards and Committees and is President for the International Society for Melanoma Research (past president from 2021).